Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
NK cell subsets define sustained remission in rheumatoid arthritis
Carl Coyle, … , Rowann Bowcutt, Esperanza Perucha
Carl Coyle, … , Rowann Bowcutt, Esperanza Perucha
Published October 17, 2024
Citation Information: JCI Insight. 2024;9(23):e182390. https://doi.org/10.1172/jci.insight.182390.
View: Text | PDF
Research Article

NK cell subsets define sustained remission in rheumatoid arthritis

  • Text
  • PDF
Abstract

Rheumatoid arthritis (RA) is an immune-mediated, chronic inflammatory condition. With modern therapeutics and evidence-based management strategies, achieving sustained remission is increasingly common. To prevent complications associated with prolonged use of immunosuppressants, drug tapering or withdrawal is recommended. However, due to the lack of tools that define immunological remission, disease flares are frequent, highlighting the need for a more precision medicine–based approach. Utilizing high-dimensional phenotyping platforms, we set out to define peripheral blood immunological signatures of sustained remission in RA. We identified that CD8+CD57+KIR2DL1+ NK cells are associated with sustained remission. Functional studies uncovered an NK cell subset characterized by normal degranulation responses and reduced proinflammatory cytokine expression, which was elevated in sustained remission. Furthermore, flow cytometric analysis of NK cells from synovial fluid combined with interrogation of a publicly available single-cell RNA-Seq dataset of synovial tissue from active RA identified a deficiency of the phenotypic characteristics associated with this NK cell remission signature. In summary, we have uncovered an immune signature of RA remission associated with compositional changes in NK cell phenotype and function that has implications for understanding the effect of sustained remission on host immunity and distinct features that may define operational tolerance in RA.

Authors

Carl Coyle, Margaret Ma, Yann Abraham, Christopher B. Mahony, Kathryn Steel, Catherine Simpson, Nadia Guerra, Adam P. Croft, Stephen Rapecki, Andrew Cope, Rowann Bowcutt, Esperanza Perucha

×

Figure 1

Peripheral blood CD8+CD57+ NK cells are associated with sustained RA remission.

Options: View larger image (or click on image) Download as PowerPoint
Peripheral blood CD8+CD57+ NK cells are associated with sustained RA rem...
(A) Longitudinal changes in DAS28 scores define key patient trajectory groups. (B) Multiple spanning tree visualization depicting differential cluster abundance analysis (comparing intermittent to stable remission) according to differences in fold change (color gradient along the y axis) and in order of increasing significance (color gradient along the x axis). (C) FreeViz analysis comparing total CD56dim NK cells (left) and total CD56dimCD57+ NK cells (right). (D) The percentage of cells in CD8+CD57+ NK cell clusters between intermittent (n = 5) and stable remission (n = 5). (E) Flow cytometry gating to define CD56dim NK cells (left) followed by subsetting based on CD8 and CD57 expression (right). (F) The proportion of CD8+CD57+ CD56dim NK cells across healthy donors (n = 6), stable remission (n = 14), intermittent remission (n = 8), and active disease (n = 8). (G) The proportion of CD8+CD57+ NK cells from paired baseline and month 12 samples from stable RA remission (n = 10). Whiskers on plots represent minimum to maximum values. P values were determined by using the Mann-Whitney U test (D), Kruskal-Wallis test with Dunn’s multiple-test correction (F), and Wilcoxon matched-pairs signed-rank test (G). *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts